Skip to search formSkip to main contentSkip to account menu

bezlotoxumab

National Institutes of Health

Related topics

Related topics

6 relations
40 ML bezlotoxumab 25 MG/ML Injection40 ML bezlotoxumab 25 MG/ML Injection [Zinplava]

Broader (2)

Antibodies, NeutralizingMonoclonal Antibodies

Narrower (2)

MK-6072Zinplava

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Assessment of Bezlotoxumab Immunogenicity
Bezlotoxumab is a fully human monoclonal antibody that binds and neutralizes Clostridium difficile toxin B. This analysis… 
2020
2020
Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials
The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B… 
2020
2020
Update Clostridioides-difficile-Infektion
Das Darmbakterium Clostridioides difficile ist eine der häufigsten Ursachen nosokomialer Diarrhöen. Die C.-difficile-Infektion… 
Review
2018
Review
2018
Bezlotoxumab for the Prevention of Clostridium difficile Recurrence.
OBJECTIVE To review the pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosing, and… 
Review
2017
Review
2017
Bezlotoxumab for the prevention of Clostridium difficile recurrence
ABSTRACT Introduction: Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of… 
2017
2017
Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
Abstract Background CDI in patients with SRI is harder to treat and is associated with higher recurrence. MODIFY I/II found that… 
Review
2017
Review
2017
"Zombie" Outbreak Caused by Synthetic Cannabinoid.
n engl j med 376;16 nejm.org April 20, 2017 1596 2. Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention… 
2017
2017
The Rising Incidence of C. difficile and Bezlotoxumab: The Targeting of Toxin B
Clostridium difficile ( C. difficile ) infection has become a growing issue facing hospitals in North America and Europe. Each… 
2016
2016
Efficacy of Bezlotoxumab (bezlo) in Prevention of Clostridium difficile Infection Recurrence (rCDI) in Patients Receiving Concomitant Systemic Antibiotics (CAs)
Background . Treatment guidelines recommend stopping CAs in patients with Clostridium dif fi cile infection (CDI), but this is not… 
2015
2015
Bezlotoxumab (BEZ) Alone and With Actoxumab (ACT) for Prevention of Recurrent C. difficile Infection (rCDI) in Patients on Standard of Care (SoC) Antibiotics: Integrated Results of 2 Phase 3 Studies…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)